![]() | |
Clinical data | |
---|---|
Trade names | Balversa |
Other names | JNJ-42756493 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a619031 |
License data |
|
Routes of administration | By mouth |
Drug class | Fibroblast growth factor receptor (FGFR) blocker [1] |
Legal status | |
Legal status |
|
Identifiers | |
| |
Chemical and physical data | |
Formula | C25H30N6O2 |
Molar mass | 446.555 g·mol−1 |
3D model ( JSmol) | |
| |
|
Erdafitinib, sold under the brand name Balversa, is a medication used to treat urothelial cancer. [2] Specifically it is used for cases which have suitable FGFR-2 or 3 mutations. [2] It is taken by mouth. [2]
Common side effects include high phosphate, mouth inflammation, tiredness, kidney problems, diarrhea, liver problems, change in taste, low magnesium, hair loss, high calcium, and muscle pain. [2] Other side effects may include infertility and vision problems. [2] Use in pregnancy may harm the baby. [2] It is a tyrosine kinase inhibitor, specifically a fibroblast growth factor receptor (FGFR) blocker. [1] [2]
Erdafitinib was approved for medical use in the United States in 2019. [2] It is not approved for use in the United Kingdom or Europe as of 2021. [1] In the United States 4 weeks of treatment costs about 21,500 USD as of 2021. [3]
![]() | |
Clinical data | |
---|---|
Trade names | Balversa |
Other names | JNJ-42756493 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a619031 |
License data |
|
Routes of administration | By mouth |
Drug class | Fibroblast growth factor receptor (FGFR) blocker [1] |
Legal status | |
Legal status |
|
Identifiers | |
| |
Chemical and physical data | |
Formula | C25H30N6O2 |
Molar mass | 446.555 g·mol−1 |
3D model ( JSmol) | |
| |
|
Erdafitinib, sold under the brand name Balversa, is a medication used to treat urothelial cancer. [2] Specifically it is used for cases which have suitable FGFR-2 or 3 mutations. [2] It is taken by mouth. [2]
Common side effects include high phosphate, mouth inflammation, tiredness, kidney problems, diarrhea, liver problems, change in taste, low magnesium, hair loss, high calcium, and muscle pain. [2] Other side effects may include infertility and vision problems. [2] Use in pregnancy may harm the baby. [2] It is a tyrosine kinase inhibitor, specifically a fibroblast growth factor receptor (FGFR) blocker. [1] [2]
Erdafitinib was approved for medical use in the United States in 2019. [2] It is not approved for use in the United Kingdom or Europe as of 2021. [1] In the United States 4 weeks of treatment costs about 21,500 USD as of 2021. [3]